Charles Schwab’s Evoke Pharma EVOK Stock Holding History

Charles Schwab’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$38K	–	3498
2020 Q4	$38K	Hold	100	–	–	﹤0.01%	3362
2020 Q3	$68K	Buy	+100	New	+$63.8K	﹤0.01%	3269

Other funds holding EVOK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wambolt & Associates Littleton, Colorado $297M AUM 17.23% 1-Year Est. Return

Charles Schwab's EVOK Position: Q1 2021 in Review

Charles Schwab sold out of Evoke Pharma (EVOK) in Q1 2021, closing a stake of 100 shares — an estimated $38K sold.

Charles Schwab first reported a position in EVOK in Q3 2020 and held it in 2 quarters. The position peaked at $68K in Q3 2020. 25 funds tracked by Wall St. Rank hold EVOK as of Q1 2021.

Charles Schwab reported no remaining Evoke Pharma position as of Q1 2021 after selling out during the quarter.
Charles Schwab sold 100 Evoke Pharma shares in Q1 2021, an estimated $38K.
Charles Schwab first reported a position in Evoke Pharma in Q3 2020 and held it in 2 quarters.
Charles Schwab's Evoke Pharma position peaked at $68K in Q3 2020.
25 funds tracked by Wall St. Rank held Evoke Pharma as of Q1 2021.

Based on Charles Schwab's 13F filing for Q1 2021, filed 17 May 2021.